Cellyan Biotechnology Co Ltd

Cellyan Biotechnology Co Ltd (HKPD) Stock Analysis

$0.182

-0.083 (-45.54%)At close

Loading chart…
High
0.467
Open
0.325
VWAP
0.27
Vol
92.55M
Mkt Cap
—
Low
0.151
Amount
24.66M
EV/EBITDA, TTM
0.00

Cellyan Biotechnology Co Ltd is an investment holding company mainly engaged in the over the counter (OTC) pharmaceutical business. The Company mainly provides two services. The supply chain services mainly provide OTC pharmaceutical cross-border e-commerce supply chain services. The procurement and distribution services mainly provide OTC pharmaceutical cross-border procurement and distribution services.

www.9zt.hk

AI analysis of Cellyan Biotechnology Co Ltd (HKPD)

sell

Given the current price of HKPD at $0.35 and a year-to-date change of -56.97%, it is not advisable to buy this asset right now. The RSI is at 33.28, indicating that the stock is oversold, but the negative momentum and declining performance over the past year (down 76.06%) raise serious concerns. Furthermore, the forward P/E ratio is at 0, suggesting a lack of expected earnings growth, and the gross margin has dropped to 10.32% in the latest quarter, which is significantly low. The primary risk is the recent compliance warning from Nasdaq, which could further depress the stock price if the company fails to meet the minimum bid price requirement.

Valuation Metrics

The current forward P/E ratio for Cellyan Biotechnology Co Ltd (HKPD) is 0.00, compared to its 5-year average forward P/E of 0.00.

Forward P/E

Strongly Undervalued
5Y Average P/E
0.00
Current P/E
0.00
Overvalued
0.00
Undervalued
0.00

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued
0.00
Undervalued
0.00

Forward P/S

Strongly Undervalued
5Y Average P/S
0.00
Current P/S
0.00
Overvalued
0.00
Undervalued
0.00

Alphio AI Price Scenarios for HKPD

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%HKPD

$1.53

Scenario price

B

Base

Base · 50%HKPD

$1.22

Scenario price

B

Bear

Bear · 25%HKPD

$0.96

Scenario price

Events Timeline

2026-06-12 (ET)

17:00:00

Cellyan Biotechnology Files $200M Mixed Securities Shelf

2026-03-27 (ET)

15:30:00

Cellyan Biotechnology Files to Sell 12.5M Class A Ordinary Shares

2025-01-15 (ET)

10:42:18

Hong Kong Pharma opens at $3.50, IPO priced at $4 per share

Show More Events

News

Show More News

HKPD FAQ — answered by Alphio AI

Cellyan Biotechnology Co Ltd is an investment holding company mainly engaged in the over the counter (OTC) pharmaceutical business. The Company mainly provides two services. The supply chain services mainly provide OTC pharmaceutical cross-border e-commerce supply chain services. The procurement and distribution services mainly provide OTC pharmaceutical cross-border procurement and distribution services. It operates in the Healthcare sector.

Given the current price of HKPD at $0.35 and a year-to-date change of -56.97%, it is not advisable to buy this asset right now. The RSI is at 33.28, indicating that the stock is oversold, but the negative momentum and declining performance over the past year (down 76.06%) raise serious concerns. Furthermore, the forward P/E ratio is at 0, suggesting a lack of expected earnings growth, and the gross margin has dropped to 10.32% in the latest quarter, which is significantly low. The primary risk is the recent compliance warning from Nasdaq, which could further depress the stock price if the company fails to meet the minimum bid price requirement.

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Get Started